Saturday 17 October 2026 Export AWHL’s income statement to Excel — free account

Aspira Women's Health Inc.

In the quarter to June 2026, revenue fell 14.9%, EPS grew 28.6%, free cash flow fell 24.6% and total debt rose 25.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years, revenue growth for five, operating cash flow growth for three; insiders bought in the last twelve months.

0.23 0.02 −8.00%

Follow AWHL

Alert me

Market cap: $2.4M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 5/9
Altman Z: −141.56
Beneish M: −7.05
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 51.86%

Capital & Financial Ratios $m

Market Cap 2.44

Revenue 8.55

Net Income (10.00)

Free Cash Flow (4.73)

Net Debt 1.47

Current Ratio 0.52

Debt/Equity (0.27)

P/E ratio 0.00

Fwd P/E (0.62)

P/S ratio 1.19

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 33.70%

Next Y EPS Growth 58.33%

Next Y revenue growth 254.38%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 6.75%

10-year low 10-year high

EV/Sales against its own 10 years 9.10%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2016	15.60	3.90 3.90 3.90 3.90

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	2	2	0
Receivables	1	1	1	1
Inventory	0	0	0	0
Other	—	—	—	—
	5	4	4	3

	2023	2024	2025	Q'26
Payables	1	2	1	3
ST’ Debt	1	1	1	1
Other	—	—	—	—
	5	5	3	5

Compound Annual Growth %

	10y	5y	3y
Sales	15.52%	14.66%	4.04%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	2	—	—	—
’25	2	2	2	2	9
’24	2	2	2	2	9
’23	2	2	2	2	9
’22	2	2	2	2	8
’21	1	2	2	2	7
’20	1	1	1	1	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(2)	—	—	—
’25	(3)	(2)	0	(2)	(7)
’24	(4)	(4)	(3)	(1)	(12)
’23	(6)	(3)	(3)	(3)	(16)
’22	(10)	(6)	(8)	(7)	(31)
’21	(5)	(6)	(8)	(8)	(27)
’20	(4)	(3)	(3)	(5)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(2)	—	—	—
’25	(3)	(2)	(1)	(2)	(7)
’24	(4)	(4)	(3)	(1)	(12)
’23	(6)	(3)	(3)	(3)	(16)
’22	(10)	(6)	(8)	(7)	(31)
’21	(5)	(7)	(8)	(8)	(28)
’20	(4)	(4)	(3)	(5)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.01	(0.05)	—	—	—
’25	(0.09)	(0.07)	(0.13)	(0.08)	(0.37)
’24	(0.39)	(0.28)	(0.23)	(0.08)	(0.93)
’23	(0.79)	(0.28)	(0.48)	(0.30)	(1.81)
’22	(1.20)	(1.05)	(1.00)	(0.60)	(3.45)
’21	(0.75)	(0.90)	(1.35)	(1.20)	(4.20)
’20	(0.60)	(0.60)	(0.60)	(0.89)	(2.70)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	11.40	14.25	4.05	4.50	7.95	22.20	4.20	2.31	0.67	0.02	Analyst estimates 2026–2028 Powerpack
	High	29.10	42.75	29.85	23.55	101.25	158.10	27.75	9.60	5.65	0.79
People
People	Employees	33	40	43	53	69	108	85	64	66	38
	Revenue/emp, $m	0.08	0.08	0.07	0.09	0.07	0.06	0.10	0.14	0.14	0.24
Income, $m
Income, $m	Revenue	3	3	3	5	5	7	8	9	9	9
	Gross margin, %	(2.12)	6.63	(2.92)	26.33	26.57	44.95	52.82	57.48	59.67	64.18
	EBT	(15)	(10)	(11)	(15)	(18)	(32)	(30)	(17)	(13)	(13)
	EBT margin, %	(566.54)	(336.33)	(372.45)	(335.76)	(384.97)	(464.80)	(365.16)	(182.32)	(142.61)	(138.67)
	Net income	(15)	(10)	(11)	(15)	(18)	(32)	(30)	(17)	(13)	(13)
	Depreciation	1	1	1	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.76	0.82	0.65	0.79	0.69	0.92	1.05	0.99	0.65	0.27
	Earnings	(4.35)	(3.00)	(2.40)	(2.70)	(2.70)	(4.20)	(3.45)	(1.81)	(0.93)	(0.37)
	Cash flow	(4.01)	(2.14)	(2.00)	(2.24)	(2.19)	(3.69)	(4.00)	(1.72)	(0.86)	(0.21)
	Capex	(0.36)	(0.02)	(0.02)	(0.02)	(0.07)	(0.02)	(0.03)	0.00	0.00	(0.01)
	Free cash flow	(4.37)	(2.16)	(2.03)	(2.27)	(2.27)	(3.72)	(4.03)	(1.72)	(0.86)	(0.22)
	Book value	1.08	0.90	1.53	1.51	1.45	4.07	0.90	(0.26)	(0.18)	(0.20)
	Shares, m	3	4	5	6	7	7	8	9	14	34
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	21.74	32.86	6.89	15.46	145.39	28.90	4.56	4.22	1.09	2.33
	P/B	15.27	30.10	2.94	8.03	69.57	6.52	5.34	0.00	0.00	0.00
	EV/Sales	20.46	31.62	4.31	13.24	142.83	23.98	3.36	4.18	1.13	2.33
	EV/FCF	(3.55)	(12.05)	(1.39)	(4.59)	(43.63)	(5.92)	(0.88)	(2.40)	(0.85)	(3.05)
Cash, $m
Cash, $m	Operating cash flow	(14)	(8)	(9)	(13)	(15)	(27)	(31)	(16)	(12)	(7)
	Capex	(1)	0	0	0	0	0	0	0	0	0
	Free cash flow	(15)	(8)	(9)	(13)	(15)	(28)	(31)	(16)	(12)	(7)
Balance, $m
Balance, $m	Working capital	4	4	8	9	13	32	11	0	(1)	1
	Total debt	2	2	1	2	5	4	3	2	2	2
	Net debt	(3)	(4)	(8)	(10)	(12)	(33)	(10)	0	0	0
	Shareholders’ equity	4	3	7	9	10	30	7	(2)	(3)	(7)
Returns, %
Returns, %	ROA	(103.30)	(147.45)	(120.30)	(120.76)	(107.11)	(104.35)	(102.25)	(141.23)	(222.82)	(233.49)
	ROIC	(2,532.86)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(140.49)	(319.12)	(215.38)	(191.78)	(194.02)	(158.74)	(160.88)	(723.45)	531.42	269.20

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NDRA ENDRA Life Sciences Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.80% (below 0%: shrinking)	n/m	+15.04% (above 0%: growing)	0.00%	0.00%	Compare
XWEL XWELL, Inc.	$7.5M	— (loss-making)	— (loss-making)	−7.08% (below 0%: shrinking)	n/m	−43.02% (below 0%: shrinking)	41.26%	(29.45%)	Compare
TTOO T2 Biosystems, Inc.	$6.5M	— (loss-making)	— (loss-making)	+34.85% (above 0%: growing)	n/m	+53.36% (above 0%: growing)	(106.60%)	(511.89%)	Compare
BIAF bioAffinity Technologies, Inc.	$5.1M	— (loss-making)	— (loss-making)	+18.99% (above 0%: growing)	n/m	−23.69% (below 0%: shrinking)	27.98%	(220.77%)	Compare
DMTKQ DermTech, Inc.	$3.3M	— (loss-making)	— (loss-making)	+10.58% (above 0%: growing)	n/m	+24.87% (above 0%: growing)	18.54%	(533.37%)	Compare
NOTVQ Inotiv, Inc.	$2.8M	— (loss-making)	— (loss-making)	−5.37% (below 0%: shrinking)	n/m	+82.66% (above 0%: growing)	20.95%	(16.41%)	Compare
ISPC iSpecimen Inc.	$2.6M	— (loss-making)	— (loss-making)	−78.70% (below 0%: shrinking)	n/m	−257.73% (below 0%: shrinking)	45.23%	(897.30%)	Compare
AWHL Aspira Women's Health Inc.	$2.4M	— (loss-making)	— (loss-making)	−14.89% (below 0%: shrinking)	n/m	−24.57% (below 0%: shrinking)	55.28%	(89.69%)
PRPH ProPhase Labs, Inc.	$1.2M	— (loss-making)	— (loss-making)	−18.93% (below 0%: shrinking)	n/m	+56.67% (above 0%: growing)	22.35%	(261.62%)	Compare
Median of peers	$4.2M	—	—	−6.22%	—	+19.96%	21.65%	(241.19%)

All 52 Diagnostics & Research stocks →